Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The self-reported perceptions of the repercussions of the disease and its treatments on daily life for young women with breast cancer and their partners.
Congard A, Christophe V, Duprez C, Baudry AS, Antoine P, Lesur A, Loustalot C, Guillemet C, Leclercq M, Segura C, Carlier D, Lefeuvre-Plesse C, Simon H, Frenel JS, Vanlemmens L. Congard A, et al. Among authors: guillemet c. J Psychosoc Oncol. 2019 Jan-Feb;37(1):50-68. doi: 10.1080/07347332.2018.1479326. Epub 2018 Oct 8. J Psychosoc Oncol. 2019. PMID: 30295567
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Venat-Bouvet L, Cany L, Catala S, Khayat D, Gambotti L, Pauporté I, Faure-Mercier C, Paget-Bailly S, Henriques J, Grouin JM; PHARE trial investigators. Pivot X, et al. Lancet. 2019 Jun 29;393(10191):2591-2598. doi: 10.1016/S0140-6736(19)30653-1. Epub 2019 Jun 6. Lancet. 2019. PMID: 31178155 Clinical Trial.
Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.
Derquin F, Floquet A, Hardy-Bessard AC, Edeline J, Lotz JP, Alexandre J, Pautier P, Angeles MA, Delanoy N, Lefeuvre-Plesse C, Cancel M, Treilleux I, Augereau P, Lavoue V, Kalbacher E, Berton Rigaud D, Selle F, Nadeau C, Gantzer J, Joly F, Guillemet C, Pomel C, Favier L, Abdeddaim C, Venat-Bouvet L, Provansal M, Fabbro M, Kaminsky MC, Lortholary A, Lecuru F, Coquard IR, de La Motte Rouge T. Derquin F, et al. Among authors: guillemet c. Gynecol Oncol. 2020 Sep;158(3):666-672. doi: 10.1016/j.ygyno.2020.06.491. Epub 2020 Jul 3. Gynecol Oncol. 2020. PMID: 32624235
Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT).
Blanc-Durand F, Lefeuvre-Plesse C, Ray-Coquard I, Chaltiel D, Floquet A, Meriaux É, Berton D, Bello-Roufai D, Guillemet C, Dupre PF, Faller É, Alexandre J, Hardy-Bressard AC, Collard O, Fabbro M, Provansal M, Kalbacher E, Genestie C, Pautier P. Blanc-Durand F, et al. Among authors: guillemet c. Gynecol Oncol. 2020 Oct;159(1):129-135. doi: 10.1016/j.ygyno.2020.07.019. Epub 2020 Jul 25. Gynecol Oncol. 2020. PMID: 32723678
Adjustment of young women with breast cancer after chemotherapy: A mediation model of emotional competence via emotional distress.
Baudry AS, Yakimova S, Congard A, Untas A, Guiu S, Lefeuvre-Plesse C, Loustalot C, Guillemet C, Segura-Djezzar C, Savoye AM, Coussy F, Frenel JS, Vanlemmens L, Christophe V. Baudry AS, et al. Among authors: guillemet c. Psychooncology. 2022 May;31(5):848-855. doi: 10.1002/pon.5876. Epub 2022 Jan 10. Psychooncology. 2022. PMID: 34989072
[Carcinosarcoma of the ovary].
Muller M, Dupre PF, Lucas B, Simon H, Malhaire JP, Guillemet C, Dessogne P, Pradier O. Muller M, et al. Among authors: guillemet c. J Gynecol Obstet Biol Reprod (Paris). 2007 Jun;36(4):399-402. doi: 10.1016/j.jgyn.2007.03.001. Epub 2007 Apr 3. J Gynecol Obstet Biol Reprod (Paris). 2007. PMID: 17408876 Free article. French.
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; PHARE trial investigators. Pivot X, et al. Lancet Oncol. 2013 Jul;14(8):741-8. doi: 10.1016/S1470-2045(13)70225-0. Epub 2013 Jun 11. Lancet Oncol. 2013. PMID: 23764181 Clinical Trial.
Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.
Clatot F, Perdrix A, Augusto L, Beaussire L, Delacour J, Calbrix C, Sefrioui D, Viailly PJ, Bubenheim M, Moldovan C, Alexandru C, Tennevet I, Rigal O, Guillemet C, Leheurteur M, Gouérant S, Petrau C, Théry JC, Picquenot JM, Veyret C, Frébourg T, Jardin F, Sarafan-Vasseur N, Di Fiore F. Clatot F, et al. Among authors: guillemet c. Oncotarget. 2016 Nov 15;7(46):74448-74459. doi: 10.18632/oncotarget.12950. Oncotarget. 2016. PMID: 27801670 Free PMC article.
61 results